Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer

INTRODUCTION: Recently in Japan, Ramucirumab (RAM) became the first anti-angiogenic agent to be approved for second-line treatment of gastric cancer. In the present study, we aimed to evaluate the efficacy and safety of RAM plus paclitaxel (PTX) in patients with unresectable and recurrent gastric ca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fukushima J Med Sci
Hauptverfasser: Hayase, Suguru, Yamada, Leo, Ujiie, Daisuke, Nirei, Azuma, Tada, Takeshi, Hanayama, Hiroyuki, Monma, Tomoyuki, Saze, Zenichiro, Ohki, Shinji, Kono, Koji
Format: Artigo
Sprache:Inglês
Veröffentlicht: The Fukushima Society of Medical Science 2019
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6509409/
https://ncbi.nlm.nih.gov/pubmed/30996218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5387/fms.2018-12
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge